No Data
No Data
Janux Therapeutics Insider Sold Shares Worth $82,125,000, According to a Recent SEC Filing
Jay Lichter, 10% Owner, Director, on June 03, 2024, sold 1,500,000 shares in Janux Therapeutics (JANX) for $82,125,000. Following the Form 4 filing with the SEC, Lichter has control over a total of 3,
Janux Therapeutics(JANX.US) Officer Sells US$45.04 Million in Common Stock
$Janux Therapeutics(JANX.US)$ Officer Reardon Tighe sold 822.72K shares of common stock on Jun 3, 2024 at an average price of $54.75 for a total value of $45.04 million.Source: Announcement What is st
JonesTrading Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $70
JonesTrading analyst Soumit Roy maintains $Janux Therapeutics(JANX.US)$ with a buy rating, and maintains the target price at $70.According to TipRanks data, the analyst has a success rate of 26.0% and
Form 144 | Janux Therapeutics(JANX.US) Director Proposes to Sell 7.21 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 3, $Janux Therapeutics(JANX.US)$ Director Avalon BioVentures I, LP intends to sell 131.2K shares of its common stock on Jun 3, with a total market value of approximately $7
Form 144 | Janux Therapeutics(JANX.US) Director Proposes to Sell 38.01 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 3, $Janux Therapeutics(JANX.US)$ Director Avalon BioVentures SPV I, L.P. intends to sell 691.53K shares of its common stock on Jun 3, with a total market value of approxima
Ambarella Posts Upbeat Results, Joins Gap, PagerDuty, Elastic And Other Big Stocks Moving Higher On Friday
U.S. stocks were mixed, with the Nasdaq Composite falling around 1% on Friday.Shares of Ambarella, Inc. (NASDAQ:AMBA) rose sharply during Friday's session following strong first-quarter earnings and u